BL‐8040 CXCR4 antagonist is safe and demonstrates...

  • Main
  • 2020 / 12
  • BL‐8040 CXCR4 antagonist is safe and demonstrates...
Cancer 2020 / 12

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

Borthakur, Gautam, Ofran, Yishai, Tallman, Martin S., Foran, James, Uy, Geoffrey L., DiPersio, John F., Showel, Margaret M., Shimoni, Avichai, Nagler, Arnon, Rowe, Jacob M., Altman, Jessica K., Abraha
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Cancer
DOI:
10.1002/cncr.33338
Date:
December, 2020
File:
PDF, 865 KB
2020
Conversion to is in progress
Conversion to is failed